

Resource Summary Report

Generated by [RRID](#) on Aug 4, 2026

AstraZeneca PheWAS Portal

RRID:SCR_021643

Type: Tool

Proper Citation

AstraZeneca PheWAS Portal (RRID:SCR_021643)

Resource Information

URL: <https://azphewas.com/>

Proper Citation: AstraZeneca PheWAS Portal (RRID:SCR_021643)

Description: Repository of gene phenotype associations for phenotypes derived from electronic health records, questionnaire data, and continuous traits computed on exomes released by UK Biobank. Repository was made available by AstraZeneca for public research.

Resource Type: data or information resource, portal

Defining Citation: [DOI:10.1038/s41586-021-03855-y](https://doi.org/10.1038/s41586-021-03855-y)

Keywords: Phenotypic data linked to medical records, rare protein coding variants, exome sequencing data, rare variants, common disease, gene-phenotype associations, AstraZeneca

Availability: Free, Freely available

Resource Name: AstraZeneca PheWAS Portal

Resource ID: SCR_021643

Record Creation Time: 20220129T080356+0000

Record Last Update: 20260803T040815+0000

Ratings and Alerts

No rating or validation information has been found for AstraZeneca PheWAS Portal.

No alerts have been found for AstraZeneca PheWAS Portal.

Data and Source Information

Usage and Citation Metrics

We found 2181 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Giri R, et al. (2026) Pathogenic OTUD3 Mutations Predispose to Ulcerative Colitis Due to Barrier Dysfunction. Cellular and molecular gastroenterology and hepatology, 20(2), 101659.

Jones J, et al. (2025) Quality by Design for Preclinical In Vitro Assay Development. Pharmaceutical statistics, 24(1), e2430.

Gonzalez-Ramos A, et al. (2025) Chemogenetics with PSAM4-GlyR decreases excitability and epileptiform activity in epileptic hippocampus. Gene therapy, 32(2), 106.

Sundell J, et al. (2025) Concentration-QT modeling demonstrates that the selective mineralocorticoid receptor modulator, balcinrenone (AZD9977), does not prolong QT interval. CPT: pharmacometrics & systems pharmacology, 14(2), 292.

Dattani S, et al. (2025) Development of Spray-Dried Micelles, Liposomes, and Solid Lipid Nanoparticles for Enhanced Stability. Pharmaceutics, 17(1).

Sartori NS, et al. (2025) Immunogenicity of SARS-CoV-2 Vaccination Schedules Including a Booster Dose in Patients with Systemic Lupus Erythematosus: Data from a Prospective Multicenter Study. Vaccines, 13(2).

Pollock C, et al. (2025) Baseline Characteristics of the DISCOVER CKD Prospective Cohort. Advances in therapy, 42(3), 1393.

Montagud AC, et al. (2025) Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain). Frontiers in public health, 13, 1490809.

Müller M, et al. (2025) Human-correlated genetic models identify precision therapy for liver cancer. Nature, 639(8055), 754.

Pourjamal N, et al. (2025) Disitamab vedotin in preclinical models of HER2-positive breast and gastric cancers resistant to trastuzumab emtansine and trastuzumab deruxtecan. Translational oncology, 53, 102284.

Neumann K, et al. (2025) Adherence to guidelines for incidental pulmonary nodules: insights from a Nordic survey. Acta oncologica (Stockholm, Sweden), 64, 22.

Sanin KI, et al. (2025) Comparing Antibody Responses to Homologous vs. Heterologous COVID-19 Vaccination: A Cross-Sectional Analysis in an Urban Bangladeshi Population. Vaccines, 13(1).

Mukenge EK, et al. (2025) Incidence of dynamic seroconversion in subjects received the first dose of the SARS-COV-2 vaccine (AstraZeneca, Moderna and Pfizer) in Kinshasa,

Democratic Republic of Congo: prospective cohort study. BMC infectious diseases, 25(1), 342.

De Miguel-Gómez L, et al. (2025) Toward human uterus tissue engineering: Uterine decellularization in a non-human primate species. Acta obstetrica et gynecologica Scandinavica, 104(3), 483.

Patel MR, et al. (2025) Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors. Targeted oncology, 20(1), 127.

Kang YK, et al. (2025) Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer. Journal for immunotherapy of cancer, 13(3).

Abraham JE, et al. (2025) Neoadjuvant PARP inhibitor scheduling in BRCA1 and BRCA2 related breast cancer: PARTNER, a randomized phase II/III trial. Nature communications, 16(1), 4269.

Antoniou P, et al. (2025) Modified pegRNAs mitigate scaffold-derived prime editing by-products. Nature communications, 16(1), 3374.

Major RW, et al. (2025) Integrated primary and secondary care optimizes the management of people with CKD-the LUCID project. Clinical kidney journal, 18(4), sfaf049.

Kjærgaard J, et al. (2025) Insulin- and exercise-induced phosphoproteomics of human skeletal muscle identify REPS1 as a regulator of muscle glucose uptake. Cell reports. Medicine, 6(6), 102163.